About


Zietchick Research Institute is the first and only life science start-up that develops new therapeutics specifically for the eye health of children and women.

The organization places its focus on the common eye disease called proliferative retinopathy, which is among the leading causes of blindness in the United States. The disease affects both males and females, although research conducted by Zietchick showed women who have the disease have an excess of hormones in their eyes. By targeting these hormones, Zietchick believes that the disease can be treated. .

The organization is developing the first eyedrops that address the unique pathophysiology of the female eye disease, which can be used in both adulthood and infancy. Furthermore, the treatment is being designed to treat the back of the eye, where the damage of retinopathy is pronounced.

Aside from this, Zietchick is also developing the first hormonal eyedrop for premature infants. When babies are born prior to their full-term, they may be deprived of hormones from the placenta that are critical in their development. By using Zietchick’s eyedrops , the eyes of premature babies will continue to develop normally even outside of the womb. This may also prevents retinopathy of prematurity from occurring.

Zietchick Research Institute hopes to prevent retinopathy for everyone through these  revolutionary treatments.

Comments

Popular posts from this blog

Identifying Early Signs of Amblyopia